EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Thioredoxin Reductase and Organometallic Complexes: A Pivotal System to Tackle Multidrug Resistant Tumors?

Michèle Salmain iD, Marie Gaschard iD, Milad Baroud iD, Elise Lepeltier iD, Gérard Jaouen, Catherine Passirani iD, Anne Vessières iD

Cancers · 06.09.2023 · 15 (18) · 4448

DOI: 10.3390/cancers15184448 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.09.2023. Verfasst von Michèle Salmain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 4 Place Jussieu, F-75005 Paris, France. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Agency of Research (ANR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancers classified as multidrug-resistant (MDR) are a family of diseases with poor prognosis despite access to increasingly sophisticated treatments. Several mechanisms explain these resistances involving both tumor cells and their microenvironment. It is now recognized that a multi-targeting approach offers a promising strategy to treat these MDR tumors. Inhibition of thioredoxin reductase (TrxR), a key enzyme in maintaining redox balance in cells, is a well-identified target for this approach. Auranofin was the first inorganic gold complex to be described as a powerful inhibitor of TrxR. In this review, we will first recall the main results obtained with this metallodrug. Then, we will focus on organometallic complexes reported as TrxR inhibitors. These include gold(I), gold(III) complexes and metallocifens, i.e., organometallic complexes of Fe and Os derived from tamoxifen. In these families of complexes, similarities and differences in the molecular mechanisms of TrxR inhibition will be highlighted. Finally, the possible relationship between TrxR inhibition and cytotoxicity will be discussed and put into perspective with their mode of action.

Schlagwörter

Stichwörter der Autor:innen

N-heterocyclic carbeneauranofincancerferrocenegoldorganometallic complexesthioredoxin reductase

Autor:innen und Institutionen

  • Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire (IPCM), 4 Place Jussieu, F-75005 Paris, France.
  • Micro & Nanomedecines Translationnelles (MINT), University of Angers, Inserm, The National Center for Scientific Research (CNRS), SFR ICAT, F-49000 Angers, France.

ORCID-Profile: Michèle Salmain, Marie Gaschard, Milad Baroud, Elise Lepeltier, Catherine Passirani, Anne Vessières

Förderung

  • National Agency of Research (ANR)

Zitieren

APA

Salmain, M., Gaschard, M., Baroud, M., Lepeltier, E., Jaouen, G., Passirani, C., & Vessières, A. (2023). Thioredoxin Reductase and Organometallic Complexes: A Pivotal System to Tackle Multidrug Resistant Tumors?. Cancers, 15(18), 4448. https://doi.org/10.3390/cancers15184448

Vancouver

Salmain M, Gaschard M, Baroud M, Lepeltier E, Jaouen G, Passirani C, et al. Thioredoxin Reductase and Organometallic Complexes: A Pivotal System to Tackle Multidrug Resistant Tumors?. Cancers. 2023;15(18):4448. doi:10.3390/cancers15184448

BibTeX
@article{Salmain2023,
  author = {Salmain, Michèle and Gaschard, Marie and Baroud, Milad and Lepeltier, Elise and Jaouen, Gérard and Passirani, Catherine and Vessières, Anne},
  title = {Thioredoxin Reductase and Organometallic Complexes: A Pivotal System to Tackle Multidrug Resistant Tumors?},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {18},
  pages = {4448},
  doi = {10.3390/cancers15184448}
}
Kostenlos starten →